What Is the Best Risk-Reducing Decision for Breast Cancer Patients With BRCA1/2 Mutation?
Abstract
N/A
Full text article
References
Casaubon JT, Regan JP. BRCA 1 and 2. StatPearls. Treasure Island (FL). 2018.
Guo F, Hirth JM, Lin Y-l, Richardson G, Levine L, et al. Use of BRCA mutation test in the US, 2004–2014. American journal of preventive medicine. 2017;52(6):702-9.
Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips KA, Mooij TM, et al. Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. JAMA. 2017;317(23):2402-16.
Salhab M, Bismohun S, Mokbel K. Risk-reducing strategies for women carrying brca1/2 mutations with a focus on prophylactic surgery. BMC Women's Health. 2010;10:28.
Lindor NM, Goldgar DE, Tavtigian SV, Plon SE, Couch FJ. BRCA1/2 Sequence Variants of Uncertain Significance: A Primer for Providers to Assist in Discussions and in Medical Management. The Oncologist. 2013;18(5):518-24.
McCarthy AM, Armstrong K. The Role of Testing for BRCA1 and BRCA2 Mutations in Cancer Prevention. JAMA internal medicine. 2014;174(7):1023-4.
Padamsee TJ, Wills CE, Yee LD, Paskett ED. Decision making for breast cancer prevention among women at elevated risk. Breast Cancer Research : BCR. 2017;19:34.
Smith KL, Isaacs C. BRCA mutation testing in determining breast cancer therapy. Cancer J. 2011;17(6):492-9.
Giannakeas V, Narod SA. The expected benefit of preventive mastectomy on breast cancer incidence and mortality in BRCA mutation carriers, by age at mastectomy. Breast Cancer Res Treat. 2018;167(1):263-7.
Kauff ND, Domchek SM, Friebel TM, Robson ME, Lee J, et al. Risk-reducing salpingo-oophorectomy for the prevention of BRCA1-and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. Journal of Clinical Oncology. 2008;26(8):1331.
Copson ER, Maishman TC, Tapper WJ, Cutress RI, Greville-Heygate S, et al. Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study. The Lancet Oncology. 2018;19(2):169-80.
Nilsson MP, Hartman L, Kristoffersson U, Johannsson OT, Borg A, et al. High risk of in-breast tumor recurrence after BRCA1/2-associated breast cancer. Breast Cancer Res Treat. 2014;147(3):571-8.
Metcalfe K, Gershman S, Ghadirian P, Lynch HT, Snyder C, et al. Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysis. BMJ. 2014;348:g226.
Stan DL, Shuster LT, Wick MJ, Swanson CL, Pruthi S, et al. Challenging and Complex Decisions in the Management of the BRCA Mutation Carrier. Journal of Women's Health. 2013;22(10):825-34.
Liede A, Mansfield CA, Metcalfe KA, Price MA, Snyder C, et al. Preferences for breast cancer risk reduction among BRCA1/BRCA2 mutation carriers: a discrete-choice experiment. Breast Cancer Research and Treatment. 2017;165(2):433-44.
Authors
Copyright (c) 2018 Archives of Breast Cancer
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright©. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non-Commercial 4.0 International License, which permits copy and redistribution of the material in any medium or format or adapt, remix, transform, and build upon the material for any purpose, except for commercial purposes.